NCT01350921 is a Phase 1 clinical trial of Ticagrelor in Drug Drug Interaction, sponsored by AstraZeneca.

Who is sponsoring NCT01350921?

NCT01350921 is sponsored by AstraZeneca.

What drugs are being tested in NCT01350921?

Interventions in NCT01350921: Ticagrelor, Venlaflaxin.

What condition does NCT01350921 study?

NCT01350921 studies Drug Drug Interaction.

Is NCT01350921 still recruiting?

NCT01350921 is currently completed. Last updated 29 March 2012.

Last reviewed 2012-03-29 · How we verify

NCT01350921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Sequential, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of Ticagrelor and Venlafaxine Given Concomitantly in Healthy Subjects Aged 18 to 45 Years

Completed Phase 1 Last updated 29 March 2012

What this trial tests

Phase 1 trial testing Ticagrelor in Drug Drug Interaction in 22 participants. Completed in 1 March 2012.

Timeline

1 May 2011

Primary endpoint
1 March 2012

1 March 2012

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	22
Start date	1 May 2011
Primary completion	1 March 2012
Estimated completion	1 March 2012
Sites	2 locations across United States, Sweden

Drugs / interventions tested

Ticagrelor (ticagrelor) — full drug profile →
Venlaflaxin — full drug profile →

Conditions studied

Drug Drug Interaction — all drugs for Drug Drug Interaction →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 45, any sex, with Drug Drug Interaction. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

area under the plasma concentration-time curve during a dosing interval (AUCτ) and observed maximum plasma concentration (Cmax)
Time frame: Multiple assessments during day 8 and 9.
Venlafaxine and O-desmethylvenlafaxine (ODV) on Day 8 (after multiple dose administration of venlafaxine for 4 days) and Day 9 (after concomitant administration of venlafaxine and ticagrelor):

Sponsor's own description

Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken together in healthy volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ticagrelor

Trials testing the same drug.

NCT06451198 — IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome · Phase 4 · recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
NCT06584812 — Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects · Phase 1 · completed
NCT06554821 — A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy · Phase 1 · completed
NCT06301776 — A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01350921 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 29 March 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01350921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing